<DOC>
	<DOCNO>NCT02337660</DOCNO>
	<brief_summary>The purpose study examine whether non-alcoholic fatty liver disease ( NAFLD ) associate hepatic glucagon resistance hyperglucagonemia .</brief_summary>
	<brief_title>Involvement Steatosis-induced Glucagon Resistance Hyperglucagonaemia</brief_title>
	<detailed_description>Hyperglucagonemia common condition obesity , prediabetes type 2 diabetes . It increase hepatic glucose production , thus contribute type 2-diabetic hyperglycemia . In current study wish examine whether non-alcoholic fatty disease ( NAFLD ) result hepatic glucagon resistance . This could result hyperglucagonemia feedback mechanism act level pancreatic alpha cell . Cirrhosis type 1 diabetes , respectively , previously show associate hepatic glucagon resistance examine relation NAFLD humans far .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Normal fast plasma glucose HbA1c &lt; 6.0 % Between 18.5 25 kg/m2 30 40 kg/m2 Normal haemoglobin Normal coagulation factor II , VII X , INR thrombocytes Age 25 year Informed consent Diabetes Prediabetes ( impaired glucose tolerance and/or impair fast plasma glucose ) Firstdegree relatives diabetes Nephropathy ( eGFR &lt; 60ml/min and/or albuminuria ) Liver disease ( ALAT and/or serum ASAT &gt; 2x normal value ) Use anticoagulative medicine like Clopidogrel og Warfarin Pregnancy and/or breastfeed Age 80 year Any condition investigator feel would interfere trial participation</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>